Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Although naturally occurring proteins form stable defined tertiary structures, it is well known that many proteins with non-natural sequences have unstructured conformations 1,2. This suggests that ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Abstract: A new approach to the permutation problem for Blind Source Separation (BSS) in the frequency domain is presented. The independence of the separation across the frequencies, and thus the ...
Run the live explorer — the heart of the project: python experiments/interactive_rha_explorer.py Drag the red observer to move through infinite space Adjust the ...
For privacy reasons, the public repository does not contain any real patient‑level values or even simulated values. The files in data_example/ are templates: they contain column headers only, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results